NovaBay Pharmaceuticals Files S-1/A Amendment
Ticker: NBY · Form: S-1/A · Filed: Jul 15, 2024 · CIK: 1389545
Sentiment: neutral
Topics: sec-filing, registration-statement, pharmaceuticals
Related Tickers: NBY
TL;DR
NovaBay Pharma filed an S-1/A amendment, updating their securities registration. Keep an eye on future offerings.
AI Summary
NovaBay Pharmaceuticals, Inc. filed an S-1/A amendment on July 15, 2024, for its registration statement. The filing, with registration number 333-280423, indicates an amendment to a previous filing made on July 12, 2024. The company, incorporated in Delaware, is in the pharmaceutical preparations industry and is headquartered in Emeryville, California.
Why It Matters
This S-1/A filing is an update to NovaBay's registration statement, which is a crucial step in the process of offering securities to the public.
Risk Assessment
Risk Level: medium — S-1/A filings often precede significant corporate actions like stock offerings, which can dilute existing shareholders or signal financial needs.
Key Numbers
- 2834 — SIC Code (Primary Standard Industrial Classification for Pharmaceutical Preparations)
- 68-0454536 — IRS Number (Company's Employer Identification Number)
Key Players & Entities
- NovaBay Pharmaceuticals, Inc. (company) — Registrant
- 333-280423 (registration_number) — SEC File Number
- 2000 Powell Street, Suite 1150 Emeryville, CA 94608 (address) — Principal Executive Offices
- Justin M. Hall (person) — Chief Executive Officer and General Counsel
- Squire Patton Boggs (US) LLP (company) — Legal Counsel
FAQ
What is the purpose of this S-1/A filing?
This is an amendment to a registration statement under the Securities Act of 1933, indicating updates or changes to the original filing.
When was the original registration statement filed?
The filing indicates it is Amendment No. 2 to a Form S-1, with the current amendment filed as of July 15, 2024, and a previous date of change noted as July 12, 2024.
What industry does NovaBay Pharmaceuticals operate in?
NovaBay Pharmaceuticals, Inc. is classified under the Standard Industrial Classification code 2834, which corresponds to Pharmaceutical Preparations.
Where is NovaBay Pharmaceuticals headquartered?
The company's principal executive offices are located at 2000 Powell Street, Suite 1150, Emeryville, CA 94608.
Who is the CEO and General Counsel of NovaBay Pharmaceuticals?
Justin M. Hall serves as the Chief Executive Officer and General Counsel for NovaBay Pharmaceuticals, Inc.
Filing Stats: 4,608 words · 18 min read · ~15 pages · Grade level 15.9 · Accepted 2024-07-12 18:21:52
Key Financial Figures
- $0 — 9 shares of our common stock, par value $0.01, or common stock, and up to 1,521,73
- $2.30 — o purchase one share of common stock is $2.30. Each Series F-1 warrant will have an e
Filing Documents
- nby20240712_s1a.htm (S-1/A) — 594KB
- ex_697927.htm (EX-5.1) — 15KB
- a01.jpg (GRAPHIC) — 40KB
- a02.jpg (GRAPHIC) — 23KB
- a03.jpg (GRAPHIC) — 19KB
- logo01.jpg (GRAPHIC) — 9KB
- logo02.jpg (GRAPHIC) — 11KB
- logo.jpg (GRAPHIC) — 7KB
- 0001437749-24-022700.txt ( ) — 759KB
Risk Factors
Risk Factors 13 Special Note Regarding Forward-Looking Statements 25
Use of Proceeds
Use of Proceeds 26 Dividend Policy 27
Dilution
Dilution 28 Principal Stockholders 30
Description of Capital Stock
Description of Capital Stock 31
Description of Securities We Are Offering
Description of Securities We Are Offering 35
Underwriting
Underwriting 37 Legal Matters 40 Experts 40 Where You Can Find More Information 40 Incorporation of Certain Documents by Reference 40 ABOUT THIS PROSPECTUS This registration statement filed with the Securities and Exchange Commission, or the SEC, includes exhibits and documents incorporated by reference that provide more detail on the matters discussed in this prospectus. You should read this prospectus, the related exhibits filed with the SEC and the documents incorporated by reference herein before making your investment decision. You should rely only on the information that we have included or incorporated by reference in this prospectus and any related free writing prospectus that we may authorize to be provided to you. We have not, and the underwriter has not, authorized anyone to provide you with information or to make any representation that is in addition to, or different from, that contained or incorporated by reference in this prospectus or contained in any permitted free writing prospectuses we have authorized for use in connection with this offering. If anyone provides you with different or inconsistent information, you should not rely on it as having been authorized by us in making a decision about whether to invest in the securities. We take no responsibility for, and cannot provide any assurance as to the reliability of, any other information that others may provide to you. The information contained in this prospectus, any related free writing prospectus and the documents incorporated by reference herein are accurate only as of their respective dates, regardless of the time of delivery of any such document or the time of any sale of the securities. Our business, assets, financial condition, results of operations and prospects may have changed since those dates. Therefore, you should not assume that the information contained in this prospectus or any related free writing prospectus is accurate on any date subsequent to the date set forth